Anti-AKR1C1 antibodies are immunoglobulins that specifically recognize and bind AKR1C1, the gene encoding aldo-keto reductase family 1 member C1 in humans. In research applications, these antibodies are used to detect AKR1C1 in tissue samples, cell lysates, and cultured cells. AKR1C1 is a cytosolic enzyme that catalyzes the NADPH-dependent reduction of ketosteroids to hydroxysteroids, contributing to neurosteroid metabolism and generating steroids that modulate neural excitability. Because AKR1C1 activity also influences drug and xenobiotic metabolism, it is studied in both endocrine and cancer drug-resistance research.
Catalog highlights and purchasing considerations
About the Biocompare AKR1C1 antibody catalog
The Biocompare antibody search tool lists AKR1C1 antibodies from a wide range of suppliers, with western blot, immunohistochemistry, and flow cytometry among the most common validated applications. Listings may also appear as cross-reactive with the closely related paralog AKR1C2, reflecting the high sequence similarity between AKR1C family members, or under the earlier name DDH. Several AKR1C1 antibodies mentioned here have been cited across a range of cancer research, including studies on Nrf2/ARE signaling in hair growth promotion, environmental nitroarene mutagenicity, and AKR1C1-mediated lenvatinib resistance in hepatocellular carcinoma.
Considerations when choosing an AKR1C1 antibody for research
Confirm that the antibody's intended target is accurate, as many genes carry synonym symbols that can create ambiguity across suppliers. Specificity should be verified against the immunogen sequence or region listed on the product datasheet, since antibodies raised against different epitopes of the same protein can behave differently across applications. Beyond specificity, several target-related attributes can affect antibody binding, including subcellular location, extracellular and cytoplasmic domain boundaries for membrane-associated targets, tissue specificity, post-translational modifications, and the presence of additional isoforms or disease-associated variants. In parallel, antibody-specific selection criteria warrant consideration, including clonality (monoclonal versus polyclonal), host species, species reactivity, and conjugate or label choice suited to the detection method. Supplier validation data, such as western blot bands at the expected molecular weight, immunohistochemistry staining patterns consistent with known tissue distribution, and knockout or knockdown controls, should also be carefully reviewed before purchase.